Top latest Five LY 3000328 Urban news
All enrolled sufferers who gained at the least one dose of zosuquidar or placebo during induction have been monitored for that prevalence of adverse occasions (439 individuals, 219 on zosuquidar and 210 on placebo). The most typical adverse functions ended up associated with the period of extended and significant myelosuppression as is expected wit